Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
ImmuPharma ( (GB:IMM) ) just unveiled an update.
ImmuPharma PLC announced its final results for the year ending December 31, 2024, highlighting significant scientific progress in its P140 autoimmune technology platform. The company reported a reduced loss of £2.5 million compared to the previous year and completed a £2.91 million fundraise. Key advancements include groundbreaking preclinical research findings that enhance the understanding of autoimmune disease mechanisms and confirm the unique, non-immunosuppressive mechanism of action of P140. These developments strengthen ImmuPharma’s intellectual property portfolio and open up new partnering opportunities. The company is focused on advancing its late-stage clinical assets and expanding its anti-infective program, positioning itself as a leader in autoimmune disease treatment.
More about ImmuPharma
ImmuPharma PLC is a specialist drug discovery and development company focused on creating innovative therapies, particularly in the field of autoimmune diseases. The company is known for its P140 technology platform, which is aimed at treating autoimmune diseases like systemic lupus erythematosus (SLE) and chronic inflammatory demyelinating polyneuropathy (CIDP). ImmuPharma is actively engaged in research and development, as well as seeking global commercial partnerships to advance its pipeline.
Average Trading Volume: 3,086,600
Technical Sentiment Signal: Buy
Current Market Cap: £16.77M
See more data about IMM stock on TipRanks’ Stock Analysis page.